Monoclonal Antibodies in Immunodiagnosis and Immunotherapy最新文献_第3页

Epitope Mapping of an Anti-CD44v4 Monoclonal Antibody (C₄₄Mab-108) Using Enzyme-Linked Immunosorbent Assay. 利用酶联免疫吸附试验绘制抗 CD44v4 单克隆抗体（C44Mab-108）的表位图。

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2024-06-01 Epub Date: 2024-03-20 DOI: 10.1089/mab.2023.0022

Hiroyuki Suzuki, Mayuki Tawara, Aoi Hirayama, Nohara Goto, Tomohiro Tanaka, Mika K Kaneko, Yukinari Kato

{"title":"Epitope Mapping of an Anti-CD44v4 Monoclonal Antibody (C44Mab-108) Using Enzyme-Linked Immunosorbent Assay.","authors":"Hiroyuki Suzuki, Mayuki Tawara, Aoi Hirayama, Nohara Goto, Tomohiro Tanaka, Mika K Kaneko, Yukinari Kato","doi":"10.1089/mab.2023.0022","DOIUrl":"10.1089/mab.2023.0022","url":null,"abstract":"CD44 is a type I transmembrane glycoprotein and possesses various isoforms which are largely classified into CD44 standard (CD44s) and CD44 variant (CD44v) isoforms. Some variant-encoded regions play critical roles in tumor progression. However, the function of CD44 variant 4 (CD44v4)-encoded region has not been fully understood. Using peptide immunization, we developed an anti-CD44v4 monoclonal antibody, C44Mab-108, which is useful for flow cytometry, western blotting, and immunohistochemistry. In this study, we determined the critical epitope of C44Mab-108 by enzyme-linked immunosorbent assay (ELISA). We used the alanine (or glycine)-substituted peptides of the CD44v4-encoded region (amino acids 271-290 of human CD44v3-10) and found that C44Mab-108 did not recognize the alanine-substituted peptides of D280A and W281A. Furthermore, these peptides could not inhibit the recognition of C44Mab-108 in flow cytometry and immunohistochemistry. The results indicate that the critical binding epitope of C44Mab-108 includes Asp280 and Trp281 of CD44v3-10.","PeriodicalId":53514,"journal":{"name":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy","volume":" ","pages":"85-89"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140177677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H2Mab-250/H2CasMab-2 for Breast Cancers'' by Kaneko et al. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 2024;43(2):35-43; doi: 10.1089/mab.2023.0033. 更正：建立新型癌症特异性抗 HER2 单克隆抗体 H2Mab-250/H2CasMab-2 治疗乳腺癌''，Kaneko 等著，《免疫诊断和免疫疗法中的单克隆抗体》，2024;43(2):35-43; doi: 10.1089/mab.2023.0033。

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2024-04-16 DOI: 10.1089/mab.2023.0033.correx

引用次数: 0

The Gift That Keeps on Giving. 送人玫瑰，手有余香。

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2024-04-01 DOI: 10.1089/mab.2024.29018.editorial

Thomas Kieber-Emmons

引用次数: 0

Epitope Mapping of an Anti-Mouse CD39 Monoclonal Antibody Using PA Scanning and RIEDL Scanning. 利用 PA 扫描和 RIEDL 扫描绘制抗小鼠 CD39 单克隆抗体的表位图。

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2024-04-01 Epub Date: 2024-03-20 DOI: 10.1089/mab.2023.0029

Yuki Okada, Hiroyuki Suzuki, Tomohiro Tanaka, Mika K Kaneko, Yukinari Kato

{"title":"Epitope Mapping of an Anti-Mouse CD39 Monoclonal Antibody Using PA Scanning and RIEDL Scanning.","authors":"Yuki Okada, Hiroyuki Suzuki, Tomohiro Tanaka, Mika K Kaneko, Yukinari Kato","doi":"10.1089/mab.2023.0029","DOIUrl":"10.1089/mab.2023.0029","url":null,"abstract":"A cell-surface ectonucleotidase CD39 mediates the conversion of extracellular adenosine triphosphate into immunosuppressive adenosine with another ectonucleotidase CD73. The elevated adenosine in the tumor microenvironment attenuates antitumor immunity, which promotes tumor cell immunologic escape and progression. Anti-CD39 monoclonal antibodies (mAbs), which suppress the enzymatic activity, can be applied to antitumor therapy. Therefore, an understanding of the relationship between the inhibitory activity and epitope of mAbs is important. We previously established an anti-mouse CD39 (anti-mCD39) mAb, C39Mab-1 using the Cell-Based Immunization and Screening method. In this study, we determined the critical epitope of C39Mab-1 using flow cytometry. We performed the PA tag (12 amino acids [aa])-substituted analysis (named PA scanning) and RIEDL tag (5 aa)-substituted analysis (named RIEDL scanning) to determine the critical epitope of C39Mab-1 using flow cytometry. By the combination of PA scanning and RIEDL scanning, we identified the conformational epitope, spanning three segments of 275-279, 282-291, and 306-323 aa of mCD39. These analyses would contribute to the identification of the conformational epitope of membrane proteins.","PeriodicalId":53514,"journal":{"name":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy","volume":" ","pages":"44-52"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140177678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Establishment of a Novel Anti-Mouse CCR1 Monoclonal Antibody C₁Mab-6. 建立新型抗小鼠 CCR1 单克隆抗体 C1Mab-6。

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2024-04-01 Epub Date: 2024-03-21 DOI: 10.1089/mab.2023.0032

Tsunenori Ouchida, Yu Isoda, Takuro Nakamura, Miyuki Yanaka, Tomohiro Tanaka, Saori Handa, Mika K Kaneko, Hiroyuki Suzuki, Yukinari Kato

{"title":"Establishment of a Novel Anti-Mouse CCR1 Monoclonal Antibody C1Mab-6.","authors":"Tsunenori Ouchida, Yu Isoda, Takuro Nakamura, Miyuki Yanaka, Tomohiro Tanaka, Saori Handa, Mika K Kaneko, Hiroyuki Suzuki, Yukinari Kato","doi":"10.1089/mab.2023.0032","DOIUrl":"10.1089/mab.2023.0032","url":null,"abstract":"C-C motif chemokine receptor 1 (CCR1/CD191) is a member of G-protein-coupled receptors and is expressed on myeloid cells, such as neutrophils and macrophages. Because the CCR1 signaling promotes tumor expansion in the tumor microenvironment (TME), the modification of TME is an effective strategy for cancer therapy. Although CCR1 is an attractive target for solid tumors and hematological malignancies, therapeutic agents for CCR1 have not been approved. Here, we established a novel anti-mouse CCR1 (mCCR1) monoclonal antibody (mAb), C1Mab-6 (rat IgG2b, kappa), using the Cell-Based Immunization and Screening method. Flow cytometry and Western blot analyses showed that C1Mab-6 recognizes mCCR1 specifically. The dissociation constant of C1Mab-6 for mCCR1-overexpressed Chinese hamster ovary-K1 was determined as 3.9 × 10-9 M, indicating that C1Mab-6 possesses a high affinity to mCCR1. These results suggest that C1Mab-6 could be a useful tool for targeting mCCR1 in preclinical mouse models.","PeriodicalId":53514,"journal":{"name":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy","volume":" ","pages":"67-74"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140186309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cx1Mab-1: A Novel Anti-mouse CXCR1 Monoclonal Antibody for Flow Cytometry. Cx1Mab-1：用于流式细胞仪的新型抗小鼠 CXCR1 单克隆抗体。

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2024-04-01 DOI: 10.1089/mab.2023.0031

Guanjie Li, Tomohiro Tanaka, Tsunenori Ouchida, M. Kaneko, Hiroyuki Suzuki, Y. Kato

{"title":"Cx1Mab-1: A Novel Anti-mouse CXCR1 Monoclonal Antibody for Flow Cytometry.","authors":"Guanjie Li, Tomohiro Tanaka, Tsunenori Ouchida, M. Kaneko, Hiroyuki Suzuki, Y. Kato","doi":"10.1089/mab.2023.0031","DOIUrl":"https://doi.org/10.1089/mab.2023.0031","url":null,"abstract":"The C-X-C motif chemokine receptor-1 (CXCR1) is a rhodopsin-like G-protein-coupled receptor, expressed on the cell surface of immune cells and tumors. CXCR1 interacts with some C-X-C chemokines, such as CXCL6, CXCL7, and CXCL8/interleukin-8, which are produced by various cells. Since CXCR1 is involved in several diseases including tumors and diabetes mellitus, drugs targeting CXCR1 have been developed. Therefore, the development of sensitive monoclonal antibodies (mAbs) for CXCR1 has been desired for the diagnosis and treatment. This study established a novel anti-mouse CXCR1 (mCXCR1) mAb, Cx1Mab-1 (rat IgG1, kappa), using the Cell-Based Immunization and Screening method. Cx1Mab-1 reacted with mCXCR1-overexpressed Chinese hamster ovary-K1 (CHO/mCXCR1) and mCXCR1-overexpressed LN229 glioblastoma (LN229/mCXCR1) in flow cytometry. Cx1Mab-1 demonstrated a high binding affinity for CHO/mCXCR1 and LN229/mCXCR1 with a dissociation constant of 2.6 × 10-9 M and 2.1 × 10-8 M, respectively. Furthermore, Cx1Mab-1 could detect mCXCR1 by Western blot analysis. These results indicated that Cx1Mab-1 is useful for detecting mCXCR1, and provides a possibility for targeting mCXCR1-expressing cells in vivo experiments.","PeriodicalId":53514,"journal":{"name":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy","volume":"374 ","pages":"59-66"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140778425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H₂Mab-250/H₂CasMab-2 for Breast Cancers. 建立治疗乳腺癌的新型癌症特异性抗 HER2 单克隆抗体 H2Mab-250/H2CasMab-2

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2024-04-01 Epub Date: 2024-04-02 DOI: 10.1089/mab.2023.0033

Mika K Kaneko, Hiroyuki Suzuki, Yukinari Kato

{"title":"Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H2Mab-250/H2CasMab-2 for Breast Cancers.","authors":"Mika K Kaneko, Hiroyuki Suzuki, Yukinari Kato","doi":"10.1089/mab.2023.0033","DOIUrl":"10.1089/mab.2023.0033","url":null,"abstract":"Overexpression of human epidermal growth factor receptor 2 (HER2) in breast and gastric cancers is an important target for monoclonal antibody (mAb) therapy. All therapeutic mAbs, including anti-HER2 mAbs, exhibit adverse effects probably due to the recognition of antigens expressed in normal cells. Therefore, tumor-selective or specific mAbs can be beneficial in reducing the adverse effects. In this study, we established a novel cancer-specific anti-HER2 monoclonal antibody, named H2Mab-250/H2CasMab-2 (IgG1, kappa). H2Mab-250 reacted with HER2-positive breast cancer BT-474 and SK-BR-3 cells. Importantly, H2Mab-250 did not react with nontransformed normal epithelial cells (HaCaT and MCF 10A) and immortalized normal epithelial cells in flow cytometry. In contrast, most anti-HER2 mAbs, such as H2Mab-119 and trastuzumab reacted with both cancer and normal epithelial cells. Immunohistochemical analysis demonstrated that H2Mab-250 possesses much higher reactivity to the HER2-positive breast cancer tissues compared with H2Mab-119, and did not react with normal tissues, including heart, breast, stomach, lung, colon, kidney, and esophagus. The epitope mapping demonstrated that the Trp614 of HER2 domain IV mainly contributes to the recognition by H2Mab-250. H2Mab-250 could contribute to the development of chimeric antigen receptor-T or antibody-drug conjugates without adverse effects for breast cancer therapy.","PeriodicalId":53514,"journal":{"name":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy","volume":" ","pages":"35-43"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140337641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Monoclonal Antibody Rat 2F11 and Rabbit A3 Against Anti-H2b3b. 鼠 2F11 和兔 A3 抗 H2b3b 的单克隆抗体。

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2024-04-01 Epub Date: 2024-04-02 DOI: 10.1089/mab.2024.0005

Saki Egashira, Taro Tachibana, Mako Nakamura, Yasuyuki Ohkawa, Akihito Harada

引用次数: 0

Production of a Monoclonal Antibody for Histone H2b Isoform H2b3b. 生产组蛋白 H2b 异构体 H2b3b 的单克隆抗体。

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2024-04-01 Epub Date: 2024-03-19 DOI: 10.1089/mab.2023.0025

Saki Egashira, Taro Tachibana, Mako Nakamura, Yasuyuki Ohkawa, Akihito Harada

引用次数: 0

PMab-314: An Anti-Giant Panda Podoplanin Monoclonal Antibody. PMab-314：抗大熊猫 Podoplanin 单克隆抗体

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2024-04-01 DOI: 10.1089/mab.2024.0003

Tsunenori Ouchida, Guanjie Li, Hiroyuki Suzuki, Miyuki Yanaka, Takuro Nakamura, Saori Handa, Tomohiro Tanaka, M. Kaneko, Y. Kato

{"title":"PMab-314: An Anti-Giant Panda Podoplanin Monoclonal Antibody.","authors":"Tsunenori Ouchida, Guanjie Li, Hiroyuki Suzuki, Miyuki Yanaka, Takuro Nakamura, Saori Handa, Tomohiro Tanaka, M. Kaneko, Y. Kato","doi":"10.1089/mab.2024.0003","DOIUrl":"https://doi.org/10.1089/mab.2024.0003","url":null,"abstract":"The giant panda (Ailuropoda melanoleuca) is one of the important species in worldwide animal conservation. Because it is essential to understand the disease of giant panda for conservation, histopathological analyses of tissues are important to understand the pathogenesis. However, monoclonal antibodies (mAbs) against giant panda-derived proteins are limited. Podoplanin (PDPN) is an essential marker of lung type I alveolar epithelial cells, kidney podocytes, and lymphatic endothelial cells. PDPN is also overexpressed in various human tumors, which are associated with poor prognosis. Here, an anti-giant panda PDPN (gpPDPN) mAb, PMab-314 (mouse IgG1, kappa) was established using the Cell-Based Immunization and Screening method. PMab-314 recognized N-terminal PA16-tagged gpPDPN-overexpressed Chinese hamster ovary-K1 cells (CHO/PA16-gpPDPN) in flow cytometry. The KD value of PMab-314 for CHO/PA16-gpPDPN was determined as 1.3 × 10-8 M. Furthermore, PMab-314 is useful for detecting gpPDPN in western blot analysis. These findings indicate that PMab-314 is a useful tool for the analyses of gpPDPN-expressed cells.","PeriodicalId":53514,"journal":{"name":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy","volume":"683 ","pages":"53-58"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140784301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0